UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000002382 |
|---|---|
| Receipt number | R000002927 |
| Scientific Title | To prevent low-dose aspirin induced peptic ulcers, which is better the use of proton pump inhibitors or histamine type2 receptor agonist; randomized controlled trial |
| Date of disclosure of the study information | 2009/09/04 |
| Last modified on | 2017/07/29 17:13:44 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
To prevent low-dose aspirin induced peptic ulcers, which is better the use of proton pump inhibitors or histamine type2 receptor agonist; randomized controlled trial
Acronym
To prevent low-dose aspirin induced peptic ulcers, which is better the use of PPI or H2RA
Scientific Title
To prevent low-dose aspirin induced peptic ulcers, which is better the use of proton pump inhibitors or histamine type2 receptor agonist; randomized controlled trial
Scientific Title:Acronym
To prevent low-dose aspirin induced peptic ulcers, which is better the use of PPI or H2RA
Region
| Japan |
Condition
Condition
the patients who are taking low dose aspirin
Classification by specialty
| Gastroenterology | Cardiology | Neurology |
| Neurosurgery | Cardiovascular surgery |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
It is said that to prevent low-dose aspirin induced peptic ulcers, proton pump inhibitors (PPI) is effective. In Western contries, it is said that taking histamine-2 receptor antagonists (H2RA) is effective to prevent those ulcers. It is necessary to prove that conclusion is truth or not in Japan.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
with or without peptic ulcer on the patients who are taking low dose aspirin
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Medicine |
Interventions/Control_1
famotidine 40mg/day
Interventions/Control_2
lansoprazole 15mg/day
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 90 | years-old | >= |
Gender
Male and Female
Key inclusion criteria
Patient who fills everything the following
1)Patients who are taking low-dose aspirin
2) Patient of 20 years or older and 90 years or younger
3) Patient who gives written informed consent
Key exclusion criteria
The patient who collides with either the following assumes that it doesn't put it in to the examination
1) Drug allergy
2)Patient who have taken PPI
3)Patient who have taken clopidogrel, antifungal agent, and corticosteroid
4)Patient who have malignant neoplasm
5)Patient who is postgastrectomy
6)pregnant and lactation
7)Liver disorder, renal disorder, bronchial asthma
Target sample size
400
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Atsushi Nakajima |
Organization
Yokohama City University Graduate School of Medicine
Division name
Gastroenterology Division
Zip code
Address
3-9 Fuku-ura, Kanagawa-ku, Yokohama, Japan
TEL
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Masahiko Inamori |
Organization
Yokohama City University Graduate School of Medicine
Division name
Gastroenterology Division
Zip code
Address
3-9 Fuku-ura, Kanagawa-ku, Yokohama, Japan
TEL
Homepage URL
Sponsor or person
Institute
Gastroenterology Division, Yokohama City University Graduate School of Medicine
Institute
Department
Personal name
Funding Source
Organization
None
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2009 | Year | 09 | Month | 04 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Terminated
Date of protocol fixation
| 2009 | Year | 08 | Month | 17 | Day |
Date of IRB
Anticipated trial start date
| 2009 | Year | 09 | Month | 01 | Day |
Last follow-up date
| 2014 | Year | 09 | Month | 01 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2009 | Year | 08 | Month | 25 | Day |
Last modified on
| 2017 | Year | 07 | Month | 29 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002927
